

Product datasheet for TA385428

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

TNFAIP3 Rabbit Monoclonal Antibody [Clone ID: R06-9B2]

Product data:

Product Type: Primary Antibodies

Clone Name: R06-9B2

Applications: IF, IHC, WB

Recommended Dilution: WB: 1/1000

IHC: 1/20-1/50 ICC/IF: 1/20-1/100

Reactivity: Human

Host: Rabbit

Isotype: IgG

Clonality: Monoclonal

Immunogen: A synthetic peptide of human TNFAIP3

Formulation: 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

Concentration: lot specific

Purification: Affinity Purified
Conjugation: Unconjugated

Storage: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Stability: 1 year

Predicted Protein Size: Calculated MW: 90 kDa; Observed MW: 82 kDa

Gene Name: TNF alpha induced protein 3

Database Link: Entrez Gene 7128 Human

D24500

P21580






Background:

Swiss-Prot Acc.P21580.Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPSinduced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.

Synonyms:


A20; MGC104522; MGC138687; MGC138688; OTUD7C; TNFA1P2

Product images:



Western blot analysis of TNFAIP3 in Hela lysates using TNFAIP3 antibody.





Immunohistochemistry analysis of paraffinembedded Human lung cancer tissue using TNFAIP3 antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.



Immunocytochemistry analysis of TNFAIP3 (green) in HL-60 using TNFAIP3 antibody,and DAPI(blue).